Cart
sales@molnova.com
Polymyxin B2
CAS No. 34503-87-2
Polymyxin B2 ( —— )
Catalog No. M37965 CAS No. 34503-87-2
Polymyxin B2 is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 385 | In Stock |
|
| 10MG | 612 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePolymyxin B2
-
NoteResearch use only, not for human use.
-
Brief DescriptionPolymyxin B2 is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria.
-
DescriptionPolymyxin B2 is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number34503-87-2
-
Formula Weight1189.45
-
Molecular FormulaC55H96N16O13
-
Purity>98% (HPLC)
-
SolubilityH2O : 125 mg/mL (105.09 mM; Need ultrasonic)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Meng M, et al. Simultaneous quantitation of polymyxin B1, polymyxin B2 and polymyxin B1-1 in human plasma and treated human urine using solid phase extraction and liquid chromatography–tandem mass spectrometry[J]. Journal of Chromatography B, 2016, 1012: 23-36.
molnova catalog
related products
-
4-O-Feruloylquinic a...
4-O-Feruloylquinic acid can be useful for the prevention of cardiovascular and other chronic diseases.
-
L-Fucitol
L-Fucitol is a galactitol analogue isolated from Myristica fragrans (Nutmeg), inhibits galactitol-positive strains of Escherichia coli K12.
-
Stressin I
Potent and selective corticotropin releasing factor receptor-1 (CRF1) agonist (Ki values are 1.5 and 224 nM for CRF1 and CRF2 receptors respectively). Increases ACTH levels and increases faecal pellet output in vivo following i.p. administration.
